Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate
Adolescent
Adult
Bayes Theorem
Body Mass Index
Child
Databases, Factual
Factor VIII
/ administration & dosage
Hemophilia A
/ drug therapy
Humans
Infusions, Intravenous
Internet-Based Intervention
/ statistics & numerical data
Models, Theoretical
Recombinant Proteins
/ administration & dosage
Young Adult
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
23
8
2019
medline:
26
5
2021
entrez:
23
8
2019
Statut:
ppublish
Résumé
Rurioctacog alfa pegol (Adynovate) is a modified recombinant factor VIII concentrate used for treating hemophilia A. Aiming to improve treatment tailoring on the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) platform for patients of all ages treated with Adynovate, we have developed and evaluated a population pharmacokinetic (PopPK) model. On the platform, PopPK models are used as priors for Bayesian forecasting that derive individual PK of hemophilia patients and are subsequently used for personalized dose regimen design. Factor activity measurements and demographic covariate data from patients infused with Adynovate were extracted from the WAPPS-Hemo database. Evaluations testing the appropriateness of Bayesian forecasting included 10-fold cross validation, a limited sampling analysis (LSA), and an external evaluation using additional independent data extracted from the WAPPS-Hemo database at a later date. The model was constructed using 650 plasma factor activity observations (555 one stage assay and 95 chromogenic assay - 4.6% below limit of quantification) measured in 154 patients from 36 hemophilia centres. A two-compartment model including between subject variability on clearance and central volume was selected as the base model. Covariates were fat free mass on clearance and central volume, age on clearance and assay type on activity. The final model was well-suited to predict PK parameters of new individuals (n = 26) from sparse observations. The development of a PopPK model for Adynovate using real-world data increases the covariate space (e.g. age) beyond what is possible from clinical trial data. This model is available on the WAPPS-Hemo platform for tailoring treatment in hemophilia A patients.
Sections du résumé
BACKGROUND AND OBJECTIVE
Rurioctacog alfa pegol (Adynovate) is a modified recombinant factor VIII concentrate used for treating hemophilia A. Aiming to improve treatment tailoring on the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) platform for patients of all ages treated with Adynovate, we have developed and evaluated a population pharmacokinetic (PopPK) model. On the platform, PopPK models are used as priors for Bayesian forecasting that derive individual PK of hemophilia patients and are subsequently used for personalized dose regimen design.
METHODS
Factor activity measurements and demographic covariate data from patients infused with Adynovate were extracted from the WAPPS-Hemo database. Evaluations testing the appropriateness of Bayesian forecasting included 10-fold cross validation, a limited sampling analysis (LSA), and an external evaluation using additional independent data extracted from the WAPPS-Hemo database at a later date.
RESULTS
The model was constructed using 650 plasma factor activity observations (555 one stage assay and 95 chromogenic assay - 4.6% below limit of quantification) measured in 154 patients from 36 hemophilia centres. A two-compartment model including between subject variability on clearance and central volume was selected as the base model. Covariates were fat free mass on clearance and central volume, age on clearance and assay type on activity. The final model was well-suited to predict PK parameters of new individuals (n = 26) from sparse observations.
CONCLUSIONS
The development of a PopPK model for Adynovate using real-world data increases the covariate space (e.g. age) beyond what is possible from clinical trial data. This model is available on the WAPPS-Hemo platform for tailoring treatment in hemophilia A patients.
Identifiants
pubmed: 31435896
doi: 10.1007/s40262-019-00809-6
pii: 10.1007/s40262-019-00809-6
doi:
Substances chimiques
Recombinant Proteins
0
BAX 855
5X3GF74R79
Factor VIII
9001-27-8
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
245-256Références
J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):439
pubmed: 31302829
AAPS J. 2009 Jun;11(2):371-80
pubmed: 19452283
Hamostaseologie. 2012;32 Suppl 1:S29-38
pubmed: 22961422
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD003429
pubmed: 21901684
Thromb Haemost. 2019 Mar;119(3):368-376
pubmed: 30685872
Ther Drug Monit. 2007 Feb;29(1):20-6
pubmed: 17304146
AAPS J. 2011 Jun;13(2):143-51
pubmed: 21302010
J Thromb Haemost. 2017 Jun;15(6):1106-1114
pubmed: 28244200
Ann Pharmacother. 2004 Oct;38(10):1702-6
pubmed: 15328391
Haemophilia. 2010 Jan;16(1):20-32
pubmed: 19845775
Blood. 2015 Aug 27;126(9):1078-85
pubmed: 26157075
Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1313-1321
pubmed: 27539370
J Thromb Haemost. 2016 Apr;14(4):724-32
pubmed: 26806557
J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):411-426
pubmed: 31104228
Haemophilia. 2016 Jan;22(1):54-64
pubmed: 26219204
Expert Rev Hematol. 2015 Apr;8(2):237-46
pubmed: 25600578
J Intern Med. 1992 Jul;232(1):25-32
pubmed: 1640190
Haemophilia. 2017 Jul;23(4):528-537
pubmed: 28220555
Thromb Haemost. 1995 Jul;74(1):1-6
pubmed: 8578439
Haemophilia. 2012 Jul;18 Suppl 4:131-5
pubmed: 22726096
J Thromb Haemost. 2017 Dec;15(12):2461-2465
pubmed: 29119666
Haemophilia. 2014 Jan;20(1):e15-22
pubmed: 24252058
Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):163-74
pubmed: 27140796
BMC Med Inform Decis Mak. 2015 Feb 07;15:7
pubmed: 25889768
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
J Thromb Haemost. 2017 Sep;15(9):1737-1746
pubmed: 28688133
Clin Pharmacokinet. 2015 Nov;54(11):1169-78
pubmed: 25940825
Haemophilia. 2010 Jul 1;16(4):597-605
pubmed: 20148977
Res Pract Thromb Haemost. 2018 May 20;2(3):535-548
pubmed: 30046759
Thromb Res. 2019 Jan;173:79-84
pubmed: 30496937
Ther Drug Monit. 2012 Oct;34(5):565-8
pubmed: 22960736
JMIR Res Protoc. 2016 Dec 15;5(4):e239
pubmed: 27977390
Haemophilia. 2016 Jul;22(4):e251-8
pubmed: 27328112
Clin Pharmacol Ther. 2007 Jul;82(1):17-20
pubmed: 17571070